Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAB 301

Drug Profile

SAB 301

Alternative Names: SAB-301

Latest Information Update: 28 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SAB Biotherapeutics
  • Developer National Institutes of Health (USA)
  • Class Antibodies; Antivirals; Monoclonal antibodies; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Middle East respiratory syndrome coronavirus

Most Recent Events

  • 28 Jun 2019 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(In volunteers) in USA (IV)
  • 10 Jan 2018 SAB Biotherapeutics completes a phase I trial for Middle East respiratory syndrome coronavirus infection (In volunteers) in USA (IV)
  • 03 Aug 2017 SAB Biotherapeutics plans a phase II trial for Middle East respiratory syndrome coronavirus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top